I-10 Christian Siebel Consensus on doxorubicin dosing in infants and children: pharmacokinetic simulations and Delphi process Wednesday 10:10-11:40 |
I-12 Erik Sjögren Bridging physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) analyses in paediatric drug development: A case study based on intravenous esomeprazole Wednesday 10:10-11:40 |
I-26 Chong Tang Population Pharmacokinetics of Tacrolimus in Pediatric Patients having undergone kidney, liver or bowel/liver transplantation. Wednesday 10:10-11:40 |
I-30 Adrien Tessier Population pharmacokinetics in adults and model-based extrapolation and dose selection in the paediatric DMD population for drug S48168/ARM210 Wednesday 10:10-11:40 |
I-31 Mita Thapar Population pharmacokinetic and exposure-lymphocyte analysis of FTY720 (Fingolimod/Gilenya) in pediatric patients with Multiple Sclerosis Wednesday 10:10-11:40 |
I-41 Chakradhara Rao Satyanarayana Uppugunduri Population pharmacokinetic model for individualized busulfan dosing in children: Annexation to the existing vast list of PopPK models for performance evaluation Wednesday 10:10-11:40 |
I-43 Louvina van der Laan Pharmacokinetics of intracellular stavudine-triphosphate in children after reduced-dose: can we improve stavudine’s safety profile? Wednesday 10:10-11:40 |
I-50 Swantje Völler Use of second-to-second physiological monitoring data for continuous evaluation of pharmacotherapy in preterm infants: an application to the respiratory stimulant doxapram Wednesday 10:10-11:40 |
II-01 Esther Encinas Population pharmacokinetic modelling of the antihistamine bilastine in children within the context of a model informed paediatric drug development approach Wednesday 15:50-17:20 |
II-02 Aline Engbers Pharmacokinetics of ibuprofen in very preterm infants with patent ductus arteriosus Wednesday 15:50-17:20 |
II-05 Dzhem Farandzha Tacrolimus Population Pharmacokinetic Analysis with Pmetrics in Infants after Liver Transplantation – preliminary data. Wednesday 15:50-17:20 |
II-17 Nicolas Frey Bridging from Intravenous to Subcutaneous Formulation of Tocilizumab for Optimal Dose Regimens in Systemic Juvenile Idiopathic Arthritis Wednesday 15:50-17:20 |
II-33 Verena Gotta Modelling urea clearance in pediatric and young adult patients on chronic hemodialysis Wednesday 15:50-17:20 |
II-71 Yu Kyong Kim A Prospective Population Pharmacokinetic Study for Recommendation of Prophylactic Fluconazole Dosage Regimen in Preterm Infants Wednesday 15:50-17:20 |
II-76 Gilbert Koch Characterization of postnatal sodium fluctuation in very preterm neonates Wednesday 15:50-17:20 |
II-77 Catherine Sherwin Tacrolimus population pharmacokinetics in paediatric kidney transplant patients Wednesday 15:50-17:20 |
III-13 Belén Pérez Solans Mechanistic model of the myeloablative effects of treosulfan and busulfan in pediatric patients undergoing bone marrow transplant Thursday 09:55-11:30 |
III-20 Ryan Beechinor A population pharmacokinetic study of high dose methotrexate treatment in infants with acute lymphoblastic leukemia: The importance of modeling inter-occasion variability across treatment cycles Thursday 09:55-11:30 |
III-22 Agathe Béranger Piperacillin dosing regimen optimization in critically ill children according to different creatinine clearances Thursday 09:55-11:30 |
III-33 Jantine Brussee Dose Individualization of CYP3A Substrates in Children: Characterization of Maturation of Intestinal and Hepatic CYP3A Activity in Children to Predict First-pass and Systemic CYP3A-mediated Metabolism Thursday 09:55-11:30 |
III-42 Pascal Chanu Pediatric plans optimization of C.E.R.A. (Continuous Erythropoietin Receptor Activator): clinical evidence obtained through a model-based integration of multisource data Thursday 09:55-11:30 |
III-49 S. Y. Amy Cheung Challenges and opportunities in the development of medical therapies for paediatric populations and the role of extrapolation Thursday 09:55-11:30 |
III-53 Francois Combes Modeling and Simulation Approach of Everolimus PK/PD Toward Completing a Pediatric Development Thursday 09:55-11:30 |
III-61 Kim Dao Evaluation of exposure to vancomycin in neonates under existing dosing regimens using a population pharmacokinetic approach Thursday 09:55-11:30 |
IV-03 Christian Laveille Population pharmacokinetics of Rimeporide in healthy volunteers and children suffering from Duchenne Muscular Dystrophy (DMD) Thursday 15:10-16:40 |
IV-11 Hyeong-Seok Lim Pharmacokinetic and Pharmacodynamic Evaluation of Intravenous Levetiracetam in Children with Epilepsy Thursday 15:10-16:40 |
IV-14 Philip Lowe Ligelizumab Paediatric Investigation Plan: exposure-response analysis in adult chronic spontaneous urticaria with simulation-based design of adolescent dose-finding Thursday 15:10-16:40 |
IV-24 Anita Mathias Joint population pharmacokinetic modelling of sofosbuvir and its metabolites (GS-566500, GS-331007) in Hepatitis C Virus (HCV)-infected adolescents receiving sofosbuvir or ledipasvir/sofosbuvir Thursday 15:10-16:40 |
IV-46 Sean Oosterholt Implications of a model-based dosing algorithm for tacrolimus in paediatric kidney transplantation Thursday 15:10-16:40 |
IV-50 - - Efficacy and toxicity of intravenous salbutamol in children with acute severe asthma: a prospective clinical PKPD study Thursday 15:10-16:40 |
IV-56 Violeta Balbas-Martinez Physiologically-Based Pharmacokinetic model for Ciprofloxacin in healthy children and approximation to children with complicated Urinary Tract Infection Thursday 15:10-16:40 |
IV-68 Theo Reijmers Population PK Modelling of Treosulfan in Paediatric Allogeneic Transplant Patients Thursday 15:10-16:40 |
IV-71 Christelle Rodrigues A population pharmacokinetic model taking into account protein binding for the sustained-release granule formulation of valproic acid in children with epilepsy Thursday 15:10-16:40 |